Most prostate cancer (PCa) patients with a biochemical failure following primary multimodality treatment (surgery and postoperative radiotherapy) relapse in the nodes. OBJECTIVE: To perform a matched-case analysis in men with lymph node recurrent PCa comparing standard of care (SOC) with metastasis-directed therapy (MDT). DESIGN, SETTING, AND PARTICIPANTS: PCa patients with a prostate-specific antigen (PSA) progression following multimodality treatment were included in this retrospective multi-institutional analysis. INTERVENTION: The SOC cohort (n=1816) received immediate or delayed androgen deprivation therapy administered at PSA progression. The MDT cohort (n=263) received either salvage lymph node dissection (n=166) or stereotactic body radiotherapy (n=97) at PSA progression to a positron emission tomography-detected nodal recurrence. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint, cancer-specific survival (CSS), was analyzed using the Kaplan-Meier method, log-rank test, Cox proportional hazards models, and propensity score-matched analyses. RESULTS AND LIMITATIONS: At a median follow-up of 70 (interquartile range: 48-98) mo, MDT was associated with an improved CSS on univariate (p=0.029) and multivariate analysis (hazard ratio: 0.33, 95% confidence interval [CI]: 0.17-0.64) adjusted for the year of radical prostatectomy (RP), age at RP, PSA at RP, time from RP to PSA progression, Gleason score, surgical margin status, pT- and pN-stage. In total, 659 men were matched (3:1 ratio). The 5-yr CSS was 98.6% (95% CI: 94.3-99.6) and 95.7% (95% CI: 93.2-97.3) for MDT and SOC, respectively (p=0.005, log-rank). The main limitations of our study are its retrospective design and lack of standardization of systemic treatment in the SOC cohort. CONCLUSIONS: MDT for nodal oligorecurrent PCa improves CSS as compared with SOC. These retrospective data from a multi-institutional pooled analysis should be considered as hypothesis-generating and inform future randomized trials in this setting. PATIENT SUMMARY: Prostate cancer patients experiencing a lymph node recurrence might benefit from local treatments directed at these lymph nodes.
Standard of care versus metastases-directed therapy for PET-detected nodal oligorecurrent prostate cancer following multimodality treatment : a multi-institutional case-control study / T. Steuber, C. Jilg, P. Tennstedt, A. De Bruycker, D. Tilki, K. Decaestecker, T. Zilli, B.A. Jereczek-Fossa, U. Wetterauer, A.L. Grosu, W. Schultze-Seemann, H. Heinzer, M. Graefen, A. Morlacco, R.J. Karnes, P. Ost. - In: EUROPEAN UROLOGY FOCUS. - ISSN 2405-4569. - 5:6(2019 Nov), pp. 1007-1013.
|Titolo:||Standard of care versus metastases-directed therapy for PET-detected nodal oligorecurrent prostate cancer following multimodality treatment : a multi-institutional case-control study|
|Parole Chiave:||choline PET/CT; neoplasm metastasis; neoplasm recurrence; oligometastasis; prostatic neoplasms|
|Settore Scientifico Disciplinare:||Settore MED/24 - Urologia|
|Data di pubblicazione:||nov-2019|
|Data ahead of print / Data di stampa:||10-mar-2018|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1016/j.euf.2018.02.015|
|Appare nelle tipologie:||01 - Articolo su periodico|
File in questo prodotto:
|195-Steuber-Standard of care-Eur Urol Focus-2018.pdf||Publisher's version/PDF||Administrator Richiedi una copia|
|1-s2.0-S2405456918300774-main.pdf||Publisher's version/PDF||Administrator Richiedi una copia|